Pharmacoepigenetics in schizophrenia: Predicting drug response

Area of Science:

• Neuroscience
• Pharmacology
• Genetics

Background:

• Individual differences in schizophrenia treatment response present a significant clinical challenge.
• Biological and psychosocial factors, including genetic and epigenetic mechanisms, contribute to this variability.
• Pharmacoepigenetics specifically examines how epigenetic mechanisms influence treatment effectiveness and adverse drug reactions.

Purpose of the Study:

• To review the epigenetic mechanisms underlying the efficacy of antipsychotic drugs in schizophrenia.
• To highlight the potential of personalized medicine approaches utilizing epigenetic markers for improved treatment outcomes.

Main Methods:

• Review of existing literature on pharmacoepigenetics and antipsychotic treatment in schizophrenia.
• Analysis of how specific antipsychotics (e.g., clozapine, haloperidol) induce epigenetic changes.
• Examination of epigenetic markers such as DNA methylation and non-coding RNAs (microRNAs, long non-coding RNAs).

Main Results:

• Antipsychotics can directly alter epigenetic modifiers (DNA methyltransferases, histone acetyltransferases).
• These drugs also indirectly impact neuroinflammatory and stress response pathways.
• Epigenetic markers show promise for predicting drug response and reducing side effects.

Conclusions:

• Epigenetic mechanisms play a crucial role in variable antipsychotic treatment response in schizophrenia.
• Personalized medicine strategies based on epigenetics could revolutionize schizophrenia treatment.
• Ethical and technical challenges must be addressed for clinical implementation of epigenetic-based strategies.